Article

Ultraviolet A-1 Phototherapy: Alternative Alopecia Areata Treatment

Author(s):

Phototherapy with ultraviolet A-1 (UVA-1) has been considered a promising treatment option for patients afflicted with alopecia areata.

Phototherapy with ultraviolet A-1 (UVA-1) has been considered a promising treatment option for patients afflicted with alopecia areata.

A research letter recently published in the International Journal of Dermatology, followed Maira E. Herz-Ruelas, MD, University Hospital, Monterrey, Mexico, and her colleagues’ study in which they treated four patients with refractory alopecia areata with UVA-1 phototherapy.

Before and after 75 sessions, the team withdrew two separate 4 mm punch scalp biopsies from alopecic plaque. Following the 75 sessions, study results indicated that all four patients showed a prominent reduction of inflammatory infiltrate, a reduction in telogen hairs, and miniaturization of hair follicles with simultaneous increase in anagen hairs.

Using the severity of alopecia tool (SALT), three patients received a score of S0 and the patient who demonstrated the most severe alopecia had a score of S1 with hair regrowth.

Furthermore, the levels of improvement were maintained even after six months post treatment.

Herz-Ruelas and colleagues concluded, “To the best of our knowledge, this is an initial report of hair regrowth with this phototherapy. We feel that UVA-1 could be included as a therapeutic alternative for patients unresponsive to previous topical or systemic pharmacological treatments.”

Related Videos
Shawn Kwatra, MD: Making the Connection Between Prurigo Nodularis, Atopic Dermatitis, and Itch
Highlighting Recent Therapies for Dermatologists, with James Del Rosso, DO
James Del Rosso, DO: Discussing What’s New in the Medicine Chest for Dermatologists
What to Look Forward To at the Fall Clinical Dermatology Conference, with Raj Chovatiya, MD, PhD
Ashfaq Marghoob, MD: Artificial Intelligence, Smartphone Use for Pigmented Lesion Classification
Major Diagnostic Challenges for Pigmented Lesions, with Ashfaq Marghoob, MD
Discussing Interim Findings on Nemolizumab for Atopic Dermatitis, with Diamant Thaçi, MD
Responding to FDA Approval of Lebrikizumab for Atopic Dermatitis, with Andrew Alexis, MD, MPH
Atypical Clinical Presentations of Blistering Disease, with Donna Culton, MD, PhD
How to Address Blistering Diseases, with Donna Culton, MD, PhD
© 2024 MJH Life Sciences

All rights reserved.